Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Conditions: Neuroendocrine Tumors Unresectable; Neuroendocrine Tumor Metastatic; Gastroenteropancreatic Neuroendocrine Tumor; Bronchial Neuroendocrine Tumor; Paraganglioma; Pheochromocytoma; Meningioma

Interventions: Drug: [203Pb]VMT-α-NET; Drug: [212Pb]VMT-α-NET

Sponsors: Perspective Therapeutics

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 2, 2026Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments